Last reviewed · How we verify
Prothionamide
Prothionamide is a Small molecule drug developed by IUATLD, Inc. It is currently in Phase 3 development. Also known as: Peteha, Pto.
Prothionamide is a medication used in the treatment of tuberculosis. It is also used in the treatment of leprosy.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Prothionamide |
|---|---|
| Also known as | Peteha, Pto |
| Sponsor | IUATLD, Inc |
| Target | Polyphenol oxidase 2 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort (PHASE3)
- Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T) (PHASE4)
- The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB (PHASE3)
- The Individualized M(X) Drug-resistant TB Treatment Strategy Study (PHASE4)
- A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China (PHASE4)
- The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prothionamide CI brief — competitive landscape report
- Prothionamide updates RSS · CI watch RSS
- IUATLD, Inc portfolio CI
Frequently asked questions about Prothionamide
What is Prothionamide?
Who makes Prothionamide?
Is Prothionamide also known as anything else?
What development phase is Prothionamide in?
What does Prothionamide target?
Related
- Target: All drugs targeting Polyphenol oxidase 2
- Manufacturer: IUATLD, Inc — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Peteha, Pto
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing